Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P50440: Variant p.Tyr203Ser

Glycine amidinotransferase, mitochondrial
Gene: GATM
Feedback?
Variant information Variant position: help 203 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Tyrosine (Y) to Serine (S) at position 203 (Y203S, p.Tyr203Ser). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and aromatic (Y) to small size and polar (S) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CCDS3; loss of glycine amidinotransferase activity. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 203 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 423 The length of the canonical sequence.
Location on the sequence: help PMAWRSRFFEYRAYRSIIKD Y FHRGAKWTTAPKPTMADELY The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         PMAWRSRFFEYRAYRSIIKDYFHRGAKWTTAPKPTMADELY

Mouse                         PMAWRSRFFEYRAYRSIIKDYFHRGAKWTTAPKPTMADELY

Rat                           PMAWRSRFFEYRAYRSIIKDYFHRGAKWTTAPKPTMADELY

Pig                           PMAWRARFFEYRAYRSIIKDYFRRGAKWTTAPKPTMADELY

Bovine                        PMAWRARFFEYRAYRTIIKDYFRRGAKWTTAPKPTMADELY

Chicken                       PMAWRARFFEYRAYRRIIKDYFNNGAKWTTAPKPTMADELY

Xenopus laevis                PMAWRARFFEYRAYRPLIKDYFRRGAKWTTAPKPTMADELY

Xenopus tropicalis            PMAWRARFFEYRAYRPLIKDYFRRGAKWTTAPKPTMADELY

Zebrafish                     PMAWRARFFEYRAYRPLIKEYFRRGARWTTAPKPTMADQLY
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 44 – 423 Glycine amidinotransferase, mitochondrial
Helix 197 – 205



Literature citations
Creatine deficiency syndrome. A treatable myopathy due to arginine-glycine amidinotransferase (AGAT) deficiency.
Nouioua S.; Cheillan D.; Zaouidi S.; Salomons G.S.; Amedjout N.; Kessaci F.; Boulahdour N.; Hamadouche T.; Tazir M.;
Neuromuscul. Disord. 23:670-674(2013)
Cited for: VARIANT CCDS3 SER-203; Arginine:glycine amidinotransferase (AGAT) deficiency: Clinical features and long term outcomes in 16 patients diagnosed worldwide.
Stockler-Ipsiroglu S.; Apatean D.; Battini R.; DeBrosse S.; Dessoffy K.; Edvardson S.; Eichler F.; Johnston K.; Koeller D.M.; Nouioua S.; Tazir M.; Verma A.; Dowling M.D.; Wierenga K.J.; Wierenga A.M.; Zhang V.; Wong L.J.;
Mol. Genet. Metab. 116:252-259(2015)
Cited for: VARIANTS CCDS3 PRO-185; SER-203 AND TRP-413; Arginine-Glycine Amidinotransferase Deficiency and Functional Characterization of Missense Variants in GATM.
DesRoches C.L.; Bruun T.; Wang P.; Marshall C.R.; Mercimek-Mahmutoglu S.;
Hum. Mutat. 37:926-932(2016)
Cited for: VARIANTS CCDS3 GLN-23; VAL-93; ASN-102; LEU-105; LYS-181; PRO-185; CYS-189; SER-203; THR-208; HIS-282; VAL-329; LEU-346; TRP-413; GLN-413 AND GLN-415; CHARACTERIZATION OF VARIANTS CCDS3 GLN-23; VAL-93; ASN-102; LEU-105; LYS-181; PRO-185; CYS-189; SER-203; THR-208; HIS-282; VAL-329; LEU-346; TRP-413; GLN-413 AND GLN-415; VARIANTS CYS-231 AND GLY-234; CHARACTERIZATION OF VARIANTS CYS-231 AND GLY-234; FUNCTION; CATALYTIC ACTIVITY;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.